| Characterization of deoxyribonucleoside transport mediated by concentrative nucleoside transporters. | Characterization of deoxyribonucleoside transport mediated by concentrative nucleoside transporters.
Yamamura T, Narumi K, Ohata T, Satoh H, Mori T, Furugen A, Kobayashi M, Iseki K. | 08/28/2021 |
| Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia. | Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia.
Jaramillo AC, Hubeek I, Broekhuizen R, Pastor-Anglada M, Kaspers GJL, Jansen G, Cloos J, Peters GJ. | 06/12/2021 |
| Brazilian Amerindian ancestry compared to Asian, European, and African Genomes.SNPs within or proximal to CIITA (rs6498115), SMC6 (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch. SNPs in ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) in the Asian comparison. | Genome-Wide Analysis in Brazilians Reveals Highly Differentiated Native American Genome Regions.
Mychaleckyj JC, Havt A, Nayak U, Pinkerton R, Farber E, Concannon P, Lima AA, Guerrant RL., Free PMC Article | 07/29/2017 |
| results that validate the newly developed structural homology model of CNT membrane architecture for human CNTs, revealed extended conformationally mobile regions within transport-domain TMs, identified pore-lining residues of functional importance, and provided evidence of an emerging novel elevator-type mechanism of transporter function. | Substituted cysteine accessibility method (SCAM) analysis of the transport domain of human concentrative nucleoside transporter 3 (hCNT3) and other family members reveals features of structural and functional importance.
Mulinta R, Yao SYM, Ng AML, Cass CE, Young JD., Free PMC Article | 06/24/2017 |
| ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N., Free PMC Article | 03/5/2016 |
| hCNT1 is a putative determinant for nucleoside analog chemoresistance in ovarian cancer. | Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Hung SW, Marrache S, Cummins S, Bhutia YD, Mody H, Hooks SB, Dhar S, Govindarajan R., Free PMC Article | 04/25/2015 |
| Human CNT1 fits the profile of a transceptor in a substrate translocation-independent manner and is likely to be relevant to tumor biology. | Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner.
Pérez-Torras S, Vidal-Pla A, Cano-Soldado P, Huber-Ruano I, Mazo A, Pastor-Anglada M., Free PMC Article | 03/1/2014 |
| MUC4 and hCNT1 as potential targets to ameliorate the response of pancreatic tumors to gemcitabine treatment. | The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N., Free PMC Article | 05/25/2013 |
| CNT1-mediated gemcitabine uptake shows a higher correlation with the CNT1 expression level than does ENT1-mediated uptake with ENT1 expression. | Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.
Choi MK. | 03/30/2013 |
| Site-directed mutagenesis analysis reveals that only one sodium binding site is affected by a mutation; lack of serine546 residue is responsible for apparent loss of CNT1 function. | Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket.
Cano-Soldado P, Gorraitz E, Errasti-Murugarren E, Casado FJ, Lostao MP, Pastor-Anglada M. | 02/11/2012 |
| our findings identify hCNT1 as a potential candidate to render drug-resistant pancreatic cancer cells amenable to chemotherapy. | CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R., Free PMC Article | 04/23/2011 |
| Two pyrimidine nucleoside analogs were potent inhibitors of CNT1, with negligible transportability and little apparent cytotoxicity, suggesting that they may have utility as cytoprotective agents. | Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
Damaraju VL, Smith KM, Mowles D, Nowak I, Karpinski E, Young JD, Robins MJ, Cass CE. | 01/1/2011 |
| Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D., Free PMC Article | 09/15/2010 |
| variability in hCNT1 and hENT1 expression in tumour and normal human breast tissue with different expression patterns related to patient prognosis and clinical outcome. | The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy.
Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG. | 09/13/2010 |
| Patients with low levels of hCNT1 achieved inferior clinical response. | Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. | 03/29/2010 |
| Clinical trial of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D., Free PMC Article | 01/20/2010 |
| The CNT1 promoter was characterized with respect to DNA response elements and their binding factors are reported. | Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression.
Klein K, Kullak-Ublick GA, Wagner M, Trauner M, Eloranta JJ. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesContribution of adenosine related genes to the risk of depression with disturbed sleep.
Gass N, Ollila HM, Utge S, Partonen T, Kronholm E, Pirkola S, Suhonen J, Silander K, Porkka-Heiskanen T, Paunio T. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia.
Enjuanes A, Benavente Y, Bosch F, Martín-Guerrero I, Colomer D, Pérez-Alvarez S, Reina O, Ardanaz MT, Jares P, García-Orad A, Pujana MA, Montserrat E, de Sanjosé S, Campo E. | 03/25/2009 |
| In nonsmall cell lung cancer CNT1 565A showed a borderline significant positive influence on the early response for carriers of the variant allele which, however, did not translate to the survival of the patients | Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Müller PJ, Dally H, Klappenecker CN, Edler L, Jäger B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A, Müller PJ, Dally H, Klappenecker CN, Edler L, Jäger B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A. | 01/21/2010 |
| 5-azacytidine as a novel substrate for hCNT1 and provides direct evidence that hCNT1 is involved in the DNA-demethylating effects of this drug | Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation.
Rius M, Stresemann C, Keller D, Brom M, Schirrmacher E, Keppler D, Lyko F. | 01/21/2010 |
| We found a strong relationship between IHC staining of hCNT3 and clinical resistance to F-ara-A therapy in chronic lymphocytic leukemia. | Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.
Tsang RY, Santos C, Ghosh S, Dabbagh L, King K, Young J, Cass CE, Mackey JR, Lai R. | 01/21/2010 |
| In NSCLC and normal tissues expression of hENT1 and hCNT1 ranged from completely negative to high. | Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.
Hubeek I, Giovannetti E, Broekhuizen AJ, Pastor-Anglada M, Kaspers GJ, Peters GJ. | 01/21/2010 |
| Report expression and hepatobiliary transport characteristics of CNT1 in sandwich-cultured human hepatocytes. | Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.
Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor-Anglada M, Tse CM, Unadkat JD., Free PMC Article | 01/21/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | See all PubMed (3) articlesImpact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients.
Naito T, Tokashiki S, Mino Y, Otsuka A, Ozono S, Kagawa Y, Kawakami J. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Müller PJ, Dally H, Klappenecker CN, Edler L, Jäger B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A, Müller PJ, Dally H, Klappenecker CN, Edler L, Jäger B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.
Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, Liu JJ, Choo TB, Tham LS, Lee HS, Goh BC, Soong R. | 06/29/2008 |
| Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.
Müller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. | 04/3/2008 |